Business
Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment
TORONTO, ON / ACCESSWIRE / September 30, 2019 / Theralase ® Technologies Inc. (" T...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer TreatmentTORONTO, ON / ACCESSWIRE / September 30, 2019 / Theralase® Technologies Inc. (\"Theralase\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDCs\") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that patient six, enrolled and treated in the Phase Ib Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Clinical Study (\"Study\"), has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 540 day clinical and cystoscopy assessment.Patient six has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 90, 180, 270, 360 and now 540 days post treatment clinical cystoscopy assessment and urine cytology, marking a new milestone for the Company.Shawn Shirazi, Ph.D., Chief Executive Officer - Drug Division, Theralase stated, \"I'm excited to share the current cancer-free status of patient 6 which further validates that a single treatment of Theralase's PhotoDynamic Therapy (\"PDT\") can lead to a duration of Complete Response (\"CR\") at 540 days post treatment for patients presenting with Bacillus Calmette Guérin (\"BCG\")-Unresponsive NMIBC. If the Company is able to achieve similar efficacy results in CR rate and duration on an interim analysis - after approximately the first 20 or 25 patients enrolled and treated - we may have the opportunity to meet with the FDA and review the results, with a focus on obtaining accelerated approval for our Anti-Cancer therapy technology.\"Theralase has initiated a Phase II NMIBC clinical study (\"Study II\"), treating the first patient at University Health Network (\"UHN\") in Toronto. Additionally, McGill University Health Center has finalized their agreement for Study II and has commenced screening and enrolling patients.Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer, Theralase stated, \"Patient 5 and 6 achieving CR at 18 months is a significant event for the Company, supporting the fact that Theralase's TLD-1433 therapy can make a significant difference in a patient's quality of life with a single treatment procedure. Moreover, our technology is multi-facet...